Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1229 • ACR Convergence 2020
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
Eulalia Rodriguez-Martín¹, Israel Nieto-Gañán¹, Borja Hernández-Breijo², Cristina Sobrino³, Carlota García-Hoz¹, Javier Bachiller-Corral⁴, Ana Martínez-Feito⁵, Victoria Navarro-Compán⁶, Paloma Lapuente-Suanzes¹, Gema Bonilla⁷, Dora Pascual-Salcedo⁸, Garbiñe Roy¹, Teresa Jurado², Pilar Nozal², Mónica Vázquez⁴, Alejandro Balsa⁷, Luisa M Villar¹ and Chamaida Plasencia⁷, ¹Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ²Hospital Universitario La Paz-Idipaz, Madrid, Spain, ³Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁶Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁷Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA…
Abstract Number: 1403 • ACR Convergence 2020
Differential Effect of Abatacept vs TNF Blockers, on the Frequency of Circulating Follicular Helper (Tfh) and Periperal Helper (Tph) T Cells in Rheumatoid Arthritis
María-José Santos-Bornez¹, Paula Fortea-Gordo¹, Laura Nuño¹, Alejandro Villalba¹, Diana Peiteado¹, Irene Monjo², Alejandro Balsa³ and Maria-Eugenia Miranda-Carus¹, ¹Hospital La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology, La Paz University Hospital- IdiPAZ, Madrid, Spain, ³Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain
Background/Purpose: CXCR5+PD-1hi follicular helper (Tfh) and CXCR5-PD-1hi peripheral helper (Tph) T cells play an important role in the pathogenesis of Rheumatoid Arthritis (RA) by providing…
Abstract Number: 1520 • ACR Convergence 2020
Characterisation of Rheumatoid and Psoriatic Arthritis Synovial Fibroblasts
Clare Cunningham¹, Sharon Ansboro¹, Sarah Wade¹, Candice Low², Ronan Mullan³, Douglas Veale⁴ and Ursula Fearon⁵, ¹Trinity College Dublin, Dublin, Ireland, ²EULAR Centre for Arthritis and Rheumatic diseases, St Vincents University Hospital, UCD, Dublin, Ireland, ³Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁴EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁵Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland
Background/Purpose: The synovial inflammation observed in Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) is characterised by synovial fibroblast hyperplasia, leukocyte infiltration, neoangiogenesis and hypoxia. These…
Abstract Number: 1564 • ACR Convergence 2020
Feasibility of Ultra-low-dose, Short-duration, Total-body Evaluation of Inflammatory Arthritis Using uEXPLORER 18F-FDG PET/CT
Soumajyoti Sarkar¹, Siba Raychaudhuri², Lorenzo Nardo³, Heather Hunt³, Denise Caudle⁴, Mike Nguyen⁴, Simon Cherry⁴, Ramsey Badawi⁴, Abhijit Chaudhari⁵ and Yasser Abdelhafez³, ¹University of California, Davis, Davis, ²Division of Rheumatology, Allergy & Clinical Immunology, University of California School of Medicine, Davis, and VA Medical Center Sacramento, Sacramento, CA, ³University of California Davis, Sacramento, CA, ⁴University of California Davis, Sacramento, ⁵University of California, Davis, Sacramento, CA
Background/Purpose: The uEXPLORER system enables the unique, simultaneous acquisition of PET data over the entire adult human body with a high-sensitivity, alongside concurrent CT data.…
Abstract Number: 1714 • ACR Convergence 2020
Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Description of disease activity status in patients with rheumatoid arthritis (RA) at fixed points in time modelled as continuous (e.g. number of swollen joints…
Abstract Number: 1730 • ACR Convergence 2020
Comparison of MBDA Score, Patient Global Assessment and Evaluator Global Assessment for Predicting Risk of Radiographic Progression
Leonard Calabrese¹, Michael Weinblatt², Nancy Shadick², Cecilie Hegaard Brahe³, Mikkel Østergaard⁴, Merete Hetland⁵, Megan Horton⁶, Darl Flake⁶ and Eric Sasso⁷, ¹Cleveland Clinic, Cleveland, OH, ²Brigham and Women's Hospital, Boston, MA, ³Center for Rheumatology and Spine diseases, Glostrup, Denmark, ⁴Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ⁵The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ⁶Myriad Genetics, Inc., Salt Lake City, UT, ⁷Myriad Autoimmune, South San Francisco, CA
Background/Purpose: To compare the abilities of MBDA score, patient global assessment (PGA) and evaluator global assessment (EGA) to assess risk for radiographic progression (RP), and…
Abstract Number: 1747 • ACR Convergence 2020
Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebo-controlled Trial (PreCePRA)
Juergen Rech¹, Hannah Schenker², Koray Tascilar¹, Melanie Hagen², Arnd Kleyer¹, David Simon¹, Larissa Valor Mendez², Verena Schoenau³, Jutta Prade⁴, Marina Sergeeva⁴, Mageshvar Sulvakumar⁵, Sandra Strobelt⁴, Laura Konerth⁴, Frank Behrens⁶, Christoph Baerwald⁷, Stephanie Finzel⁸, Reinhard Voll⁹, Axel Hueber¹⁰, Julie Roesch¹¹, Eugen Feist¹², José A. P. da Silva¹³, Arnd Doerfler¹¹, Nemanja Damjanov¹⁴, Andreas Hess¹⁵ and Georg Schett¹⁶, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, ⁴Institute for Experimental Pharmacology, Erlangen, Germany, ⁵Insitute for Experimental Pharmacology , Fau Erlangen-Nürnberg, Erlangen, Germany, ⁶CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, ⁷Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, ⁸Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, ⁹Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, ¹⁰Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, ¹¹Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, ¹²Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ¹³9.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, ¹⁴University of Belgrade Medical School, Belgrade, Serbia, ¹⁵Institute for Experimental Pharmacology, Erlangen, ¹⁶Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Personalization of RA treatment is not optimal due to lack of predictors. We previously demonstrated in RA patients that central nervous system (CNS) pain…
Abstract Number: 1765 • ACR Convergence 2020
Obstetric Outcomes in Younger Women Less Than 21 Years of Age Compared to Women Between Age 21 and 25 Years with Rheumatic Disease
Chelsey Smith¹, Christina Chambers¹, Rebecca Baer², Laura Jelliffe-Pawlowski³ and Gretchen Bandoli¹, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego, La Jolla, ³University of California San Francisco, San Francisco
Background/Purpose: Very young maternal age has been described as a risk factor for several adverse obstetric outcomes. This study aimed to investigate whether younger women…
Abstract Number: 1978 • ACR Convergence 2020
Prevalence and Factors Associated with Patient-Physician Discordance Among RA Patients Initiating Advanced Therapy
Jeffrey Curtis¹, Rose Medeiros², I-Heng Lee³, Rachel Mackey⁴, Richard Haubrich³, Hao Hu⁵, Jeffrey Greenberg⁶ and Alicea Wu³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Corrona, LLC, Waltham, MA, ³Gilead Sciences, Foster City, CA, ⁴Corrona, LLC and University of Pittsburgh, Waltham, MA, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Corrona, LLC and NYU School of Medicine, Waltham, MA
Background/Purpose: Some rheumatoid arthritis (RA) patients rate their disease activity worse than their physician does, but recent prevalence and factors associated with such discordance have…
Abstract Number: 2007 • ACR Convergence 2020
Whole Blood Transcriptional Changes Following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-Severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate
Peter Taylor¹, Bryan Downie², Emon Elboudwarej², Sam Kim², Angie Hertz², Amer Mirza², Jeff Siegel³, Rachael Hawtin² and Jinfeng Liu², ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), a selective, oral JAK1 inhibitor, has shown efficacy and safety in phase 3 studies in adults with moderately-to-severely active rheumatoid arthritis (RA).…
Abstract Number: 0032 • ACR Convergence 2020
A Prospective, Multicenter, Clinical Performance Evaluation Study for an in-vitro Diagnostics Medical Device (PREDYSTIC® Infliximab RA) for Prediction of Infliximab Responsiveness in the Treatment of Rheumatoid Arthritis
Miklos Sebeszta¹, Katalin Tauberne Jakab¹, Tamas Ponyi¹, Gyula Poor², Zsolt Hollo¹, Laszlo Szilagyi¹, Emese Kiss² and Gabor Zahuczky³, ¹Egis Pharmaceuticals, Budapest, Hungary, ²ORFI, Budapest, Hungary, ³UD Genomed, Debrecen, Hungary
Background/Purpose: Approximately 30-40% of RA patients fail to respond to first biological therapy. Predicting the patient’s responsiveness to the first biological therapy is still an…
Abstract Number: 0104 • ACR Convergence 2020
Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis
Attila Hamar¹, Anita Pusztai², Edit Végh¹, Ágnes Horváth¹, Katalin Gulyás¹, Szilvia Szamosi¹, Zsófia Pethő¹, Nóra Bodnár¹, Boglárka Soós¹, Monika Czókolyová¹, Sándor Szántó¹, Gabriella Szűcs¹, Harjit Bhattoa¹, Gábor Nagy¹, Gábor Tajti¹, Andrea Domján¹, Katalin Hodosi¹ and Zoltán Szekanecz¹, ¹University of Debrecen, Debrecen, Hungary, ²University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary
Background/Purpose: Oral JAK inhibitor, tofacitinib appeared as a new therapeutic option, beside biological therapies, which has already proven its safety and effectivity in RA, but…
Abstract Number: 0149 • ACR Convergence 2020
How Stable Are Medication Necessity Beliefs and Safety Concerns in the First Year of RA?
Viviane Ta¹, Orit Schieir², Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward Keystone⁸, Janet Pope⁹, Carter Thorne¹⁰, Diane Tin¹⁰, Nicole Andersen¹, Vivian Bykerk¹¹, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹McGill University, Montreal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ⁹Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: At RA onset, DMARDs are essential to controlling inflammation and preventing disability. In people with established RA, specific beliefs about the necessity of DMARDs…
Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Magali Zanotti-Cavazzoni¹ and Gabriela Avila², ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Sociedad Paraguaya de Reumatologia, Asuncion, Paraguay
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…
Abstract Number: 0202 • ACR Convergence 2020
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis
Kevin Winthrop¹, Tsutomu Takeuchi², Gerd Burmester³, Patrick Durez⁴, Walter Deberdt⁵, Douglas Schlichting⁶, Scott Beattie⁶, Daojun Mo⁷, Chad Walls⁶ and Josef Smolen⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ³Charité University Hospital Berlin, Berlin, Germany, ⁴Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, ⁵Eli Lilly and Company, Brussels, Belgium, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Carmel, IN, ⁸Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK)1/JAK 2 inhibitor approved for the treatment of moderately to severely active rheumatoid arthritis (RA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].